Pilot study of antithymocyte globulin in systemic sclerosis

Arthritis and Rheumatism

Volumn 39, Issue 7, 1996, Pages 1132-1137

  Matteson, Eric L ^a,b   Shbeeb, Mohammad I ^a   McCarthy, Tim G ^a   Calamia, Kenneth T ^b   Mertz, Lester E ^b   Goronzy, Jörg J ^b  

^a Manitoba Clinic   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; PARACETAMOL; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; LUNG DIFFUSION; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; VITAL CAPACITY;

ADULT; ANTILYMPHOCYTE SERUM; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; MALE; MIDDLE AGED; PILOT PROJECTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0029899152     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390709     Document Type: Article

References (11)

1. Medsger TA Jr: Systemic sclerosis (scleroderma), localized scleroderma, eosinophilic fasciitis, and calcinosis. In, Arthritis and Allied Conditions. Eleventh edition. Edited by DJ McCarty. Philadelphia, Lea and Febiger, 1989
2. Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, Singer JZ, Steen VD, Clegg DO, Ziminski CM, Alarcon GS, Luggen ME, Polisson RP, Willkens RF, Reading JD, Williams HJ, Ward JR: Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med 118:602-609, 1993
3. Masi AT: Clinical-epidemiological perspective of systemic sclerosis (scleroderma). In, Systemic Sclerosis: Scleroderma. Edited by MIV Jayson, CM Black. New York, John Wilcy and Sons Ltd., 1988
4. Korn JH: Immunologic aspects of scleroderma. Curr Opin Rheumatol 3:947-952, 1991
5. Goronzy JJ, Weyand CM: Long-term immunomodulatory effects of T lymphocyte depletion in patients with systemic sclerosis. Arthritis Rheum 33:511-519, 1990
6. Cosimi AB, Wortis HH, Delomonico FL, Russell PS: Randomized clinical trial of anti-thymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring. Surgery 80:155-163, 1976
7. Balaban EP, Zashin SJ, Geppert TD, Lipsky PE: Treatment of systemic sclerosis with antithymocyte globulin (letter). Arthritis Rheum 34:244-245, 1991
8. Black C: Anti-thymocyte globulin in treatment of systemic sclerosis. First International Symposium on the Immunotherapy of the Rheumatic Diseases. London. February 20-22, 1991
9. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F: Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis (editorial). J Rheumatol 15:202-205, 1988
10. Kahaleh MD, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC: A modified scleroderma skin scoring method. Clin Exp Rheumatol 4:367-369, 1986
11. Poole JL, Williams CA, Bloch DA, Hollak B, Spitz P: Concurrent validity of the Health Assessment Questionnaire disability index in scleroderma. Arthritis Care Res 8:189-193, 1995